Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Full Prescribing Information, Copaxone (glatiramer acetate)
Sleep and Cognitive Function in Multiple Sclerosis.
Factors in Patient Empowerment: A Survey of an Online Patient Research Network.
Rapid exacerbation of multiple sclerosis following the initiation of interferon-β: report of nine cases.
Episode 28 with Dr. Brenda Banwell on pediatric MS
Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis.
Changes in cognition, arm function and lower body function after Slow-Release Fampridine treatment.
Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis.
Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
Plasma ubiquitin?proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b.
Tumefactive multiple sclerosis presenting with tonic-clonic seizure.
Rapid, sustained and reversible pharmacodynamics of DAC HYP in MS patients supports mechanism of action via modulation of the IL-2 pathway
Interferon-beta-1b protects against multiple sclerosis-induced endothelial cells apoptosis.
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
Gordon Research Conference on Notch Signaling in Development, Regeneration & Disease
A case of posterior reversible encephalopathy syndrome associated with gilenya(®) (fingolimod) treatment for multiple sclerosis.
Inhibition of LTi Cell Development by CD25 Blockade Is Associated with Decreased Intrathecal Inflammation in Multiple Sclerosis.
Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
Mast cell inflammasome activity in the meninges regulates EAE disease severity.
Multiple sclerosis and risk of attempted and completed suicide - a cohort study.
Episode 11 with Dr. Jack Antel on remyelination and on bedside-to-bench research
Antagonism of histamine H4 receptor exacerbates clinical and pathological signs of experimental autoimmune encephalomyelitis.
Differing trends in the incidence of vascular comorbidity in MS and the general population.
EMD Serono and Pfizer announce FDA approval of Rebif® Rebidose® (interferon beta-1a)
Pages
« first
‹ previous
…
66
67
68
69
70
71
72
73
74
…
next ›
last »